Bay Street News

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 –

– Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings –

LOS ALTOS, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended March 31, 2024, and provided a business update.

“This is an exciting time for Unicycive as we progress towards the conclusion of our pivotal clinical trial for our lead asset oxylanthanum carbonate (OLC),” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “The trial is evaluating the tolerability, safety, and pharmacokinetics of clinically effective doses of OLC in patients with chronic kidney disease (CKD) on dialysis and it remains on track with topline data expected later this quarter. If approved, OLC may provide a meaningful improvement in the quality of life for CKD patients on dialysis with hyperphosphatemia by reducing the pill burden volume by more than 4-fold compared to the most prescribed phosphate binder1.”

Dr. Gupta, continued, “We are also developing UNI-494 for the prevention of delayed graft function (DGF) after kidney transplantation and other conditions related to acute kidney injury. This is an important indication as DGF is one of the most serious complications resulting from kidney transplantation. UNI-494 is advancing through the multiple ascending dose (MAD) portion of its Phase 1 study, and we expect to complete the trial and report the full results in the second half of this year.”

“A priority for us in 2024 is expanding awareness of our programs within the medical and scientific communities. This month we will be presenting important data on both OLC and UNI-494 at two of the most prominent, global nephrology meetings hosted by the National Kidney Foundation and the European Renal Association. We look forward to providing updates on our programs at these events for all of our stakeholders,” concluded Dr. Gupta.

Key Highlights

Financial Results for the Quarter Ended March 31, 2024

Licensing Revenues: There were no licensing revenues recorded for the quarter ended March 31, 2024. Licensing revenues of approximately $0.7 million were recorded in the three months ended March 31, 2023, due to an upfront payment for a licensing agreement entered into with Lotus International PTE Ltd.

Research and development (R&D) Expenses: R&D expenses were $6.8 million for the three months ended March 31, 2024, compared to $3.0 million for the three months ended March 31, 2023. The increase in research and development expenses was primarily due to one time costs related to the OLC clinical trial.

General and Administrative (G&A) Expenses: G&A expenses were $2.4 million for the three months ended March 31, 2024, compared to $1.8 million for the three months ended March 31, 2023. The increase in general and administrative expenses was primarily due to an increase in non-cash stock compensation costs.

Other Income (Expenses): Other income (expenses) was $11.8 million for the three months ended March 31, 2024, compared to $10.4 million for the three months ended March 31, 2023. The increase was due primarily to a $11.8 million change in fair value of our warrant liability.

Net Loss: Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per share of common stock, compared to a net loss of $14.8 million, or $0.97 per share of common stock, for the three months ended March 31, 2023. This increase was attributable primarily to increased drug development costs and the change in fair value of our warrant liability.

Cash Position: As of March 31, 2024, cash and cash equivalents totaled $48.9 million. The Company believes that it has sufficient resources to fund planned operations into 2026.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

1Sprague, et al, “High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders”, American Journal of Nephrology, September 2023

Investor Contact:

ir@unicycive.com 
(650) 900-5470

SOURCE: Unicycive Therapeutics, Inc.

 
Unicycive Therapeutics, Inc.
 
Balance Sheets
(In thousands, except for share and per share amounts)
             
    As of     As of  
    December 31,     March 31,  
    2023     2024  
Assets         (Unaudited)  
Current assets:            
Cash and cash equivalents   $ 9,701     $ 48,930  
Prepaid expenses and other current assets     3,698       2,746  
Total current assets     13,399       51,676  
Right of use asset, net     766       686  
Property, plant and equipment, net     26       23  
Total assets   $ 14,191     $ 52,385  
                 
Liabilities, mezzanine equity, and stockholders’ deficit                
Current liabilities:                
Accounts payable   $ 839     $ 1,240  
Accrued liabilities     3,234       3,550  
Dividends payable           208  
Warrant liability     13,134       24,941  
Operating lease liability – current     327       343  
Total current liabilities     17,534       30,282  
Operating lease liability – long term     466       372  
Total liabilities     18,000       30,654  
Commitments and contingencies (Note 8)                
Mezzanine equity:                
Series B-1 preferred stock, $0.001 par value per share – zero shares authorized at December 31, 2023, and 50,000 shares authorized at March 31, 2024; zero shares outstanding at December 31, 2023, and 50,000 shares outstanding at March 31, 2024           46,187  
Stockholders’ deficit:                
Series A-2 preferred stock, $0.001 par value per share – 43,649 Series A-2 shares authorized at December 31, 2023 and 21,388.01 Series A-2 Prime shares authorized at March 31, 2024; 43,649 Series A-2 shares outstanding at December 31, 2023 and 19,991.51 Series A-2 Prime shares outstanding at March 31, 2024            
Preferred stock: $0.001 par value per share—9,296,161 and 9,904,773 shares authorized at December 31, 2023 and March 31, 2024, respectively; zero shares issued and outstanding at December 31, 2023 and March 31, 2024            
Common stock, $0.001 par value per share – 200,000,000 shares authorized at December 31, 2023 and March 31, 2024; 34,756,049 and 37,606,630 shares issued and outstanding at December 31, 2023 and March 31, 2024, respectively     35       37  
Additional paid-in capital     60,697       61,011  
Accumulated deficit     (64,541 )     (85,504 )
Total stockholders’ deficit     (3,809 )     (24,456 )
Total liabilities and stockholders’ deficit   $ 14,191     $ 52,385  
Unicycive Therapeutics, Inc.
 
Statements of Operations
(In thousands, except for share and per share amounts)
(Unaudited) 
 
    Three Months Ended
March 31,
 
    2023     2024  
             
Licensing revenues:   $ 675     $  
                 
Operating expenses:                
Research and development     3,030       6,813  
General and administrative     1,847       2,391  
Total operating expenses     4,877       9,204  
Loss from operations     (4,202 )     (9,204 )
Other income (expenses):                
Interest income     14       69  
Interest expense     (12 )     (20 )
Change in fair value of warrant liability     (10,375 )     (11,808 )
Total other income (expenses)     (10,373 )     (11,759 )
Net loss     (14,575 )     (20,963 )
Deemed dividend to Series A-1 preferred stockholders     (192 )      
Dividend to Series B preferred stockholders           (208 )
Net loss attributable to common stockholders   $ (14,767 )   $ (21,171 )
Net loss per share attributable to common stockholders, basic and diluted   $ (0.97 )   $ (0.61 )
Weighted-average shares outstanding used in computing net loss per share, basic and diluted     15,232,406       34,912,692  

 


Bay Street News